Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:UMRX

Cogent Biosciences (UMRX) Stock Price, News & Analysis

Cogent Biosciences logo

About Cogent Biosciences Stock (NASDAQ:UMRX)

Advanced Chart

Key Stats

Today's Range
$7.18
$7.68
50-Day Range
$2.35
$13.01
52-Week Range
$0.29
$3.72
Volume
1.78 million shs
Average Volume
1.22 million shs
Market Capitalization
$314.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive UMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

UMRX Stock News Headlines

How to Collect Up To $5,917/mo From Trump’s Made In USA Boom
How to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America. But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month. Don't miss your chance to participate directly in America's industrial comeback.
Cogent Biosciences (COGT) Initiated with a Buy at Scotiabank
See More Headlines

UMRX Stock Analysis - Frequently Asked Questions

Cogent Biosciences, Inc. (NASDAQ:UMRX) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.03. The firm had revenue of $0.53 million for the quarter. Cogent Biosciences had a negative net margin of 96.84% and a negative trailing twelve-month return on equity of 87.78%.

Cogent Biosciences (UMRX) raised $75 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/11/2020
Today
7/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UMRX
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$31.83 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.50 million
Price / Cash Flow
N/A
Book Value
$1.04 per share
Price / Book
6.94

Miscellaneous

Free Float
N/A
Market Cap
$306.63 million
Optionable
Not Optionable
Beta
3.93
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:UMRX) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners